Implications of Early Diagnosis for the Development of Therapeutics for Alzheimer’s Disease
Reference72 articles.
1. Ohm TG, Muller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 1995;64:209–217.
2. Bondareff W, Mountjoy CQ, Roth M, et al. Age and histopathologic heterogeneity in Alzheimer’s disease: evidence for subtypes. Arch. Gen. Psychiat. 1987;44: 412–417.
3. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of higher-dose lecithin in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiat. 1985;48:736–742.
4. Thompson TL, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer’s disease. N. Engl. J. Med. 1990;323:445–448.
5. Schneider LS, Olin JT. Overview of clinical trials of Hydergine in dementia. Arch. Neurol. 1994;51:787–798.